The Moderna Covid-19 vaccine is prepared for administration at Union Station in Los Angeles in January. Photo:AFP
Moderna’s Omicron-specific Covid-19 vaccine shows positive results
- The US biotech firm sees the shot, which targets both the original coronavirus strain and the subvariant, as its ‘lead candidate’ for a booster this fall
- In a trial of 814 adults, the ‘bivalent’ vaccine produce 1.75 times more Omicron-specific neutralising antibodies than the original Spikevax jab
Follow your favourite topic and get notified
The Moderna Covid-19 vaccine is prepared for administration at Union Station in Los Angeles in January. Photo:AFP